The aim of this study was to investigate the effects of add-on therapy with long-acting β-agonists and leukotriene antagonists on FEV1 and exhaled nitric oxide levels (FENO) in children.
Forty-eight steroid-naïve atopic asthmatic children, 7–11 years of age, were randomly treated in four groups for two consecutive one-month periods, as follows: (1) first month: budesonide 200 μg twice daily; second month: budesonide 400 μg twice daily; (2) first month: budesonide 200 μg twice daily+formoterol 9 μg twice daily; second month: budesonide 200 μg twice daily+montelukast 5 mg once daily; (3) first month: budesonide 200 μg twice daily+montelukast 5 mg once daily; second month budesonide 200 μg+formoterol 9 μg twice daily; (4) first and second month: budesonide 400 μg twice daily.
All treatments resulted in a significant increase in lung function and a decrease in FENO compared with values at baseline. Budesonide+montelukast in combination was the most effective treatment for reducing FENO levels.
This study demonstrates that add-on therapy with montelukast plus low-dose budesonide is more effective than the addition of long-acting β-agonists or doubling the dose of budesonide for controlling FENO in asthmatic children.